|
 Technology shares led the U.S. stock market's recovery this week
from its worst correction in four years in August, thanks to gains
in Alphabet, Amazon and Microsoft, after the three companies
reported better-than-expected earnings results.
The Dow Jones industrial average rose 0.9 percent to 17,646.70, the
S&P 500 index recovered another 1.1 percent to 2,075.15, and the
Nasdaq Composite closed the week up 2.27 percent at 5,031.86.
Shares across Asia, Europe and the Americas all climbed, boosted by
Thursday's message from European Central Bank chief Mario Draghi
that he was ready to increase the ECB's bond buying program, and by
an interest rate cut by China's central bank.
Factors this coming week that may provide further support for U.S.
stocks include a Federal Reserve policy meeting, which is not
expected to raise interest rates yet, a report on U.S. third-quarter
economic growth, and earnings from Apple.
The Nasdaq 100 index, including Apple, is just 1.5 percent below its
year high and 4.0 percent from its record high back in March 2000.
Intel and Microsoft have seen their stocks recover more than 30
percent each since Aug. 25, while Amazon and Facebook rose 28
percent and 23 percent, respectively.
But the 'underperformer' among these companies has been Apple, up
only 14.8 percent from its Aug. 25 close, less than the Nasdaq 100's
15.1 percent gain in that time.
In contrast to Microsoft, Facebook, Alphabet and Amazon, Apple
shares did not post record or multi-year highs this week, even
though it rose 7.2 percent, the largest weekly gain in a year.
On Tuesday, though, Apple is expected to report $51.1 billion in
revenue, a 21.3 percent increase compared to the same quarter of
last year. Earnings are seen at $1.879 per share.
"The bar has been raised a bit on its earnings report from where it
was a week ago. The price action is telling you there's more
optimism built into it," said Michael James, managing director of
equities trading at Wedbush Securities in Los Angeles.
Options market action shows traders expect Apple shares to move
roughly 5.0 percent by the end of next week. The average move for
the stock the day after its report in the last eight quarters was
4.4 percent, up or down.
"Will an above-estimates from Apple and raised guidance help? Sure
it will. But we could still get there without that happening," said
James of the possibility of the Nasdaq 100 hitting a record.
"The power of the moves in some of these large cap tech stocks has
been breathtaking," he said.
Chip makers were also among the top five percentage gainers in the
Nasdaq 100 since the index closed at its 2015 low on Aug. 25, with
SanDisk topping the list with a 70 percent jump on the back of a
takeover bid from Western Digital.
[to top of second column] |
The overwhelming leadership from established technology companies is
a positive for this market move higher, according to Kim Forrest,
senior equity research analyst at Fort Pitt Capital Group in
Pittsburgh.
"The last time the Nasdaq 100 was the market leader a lot of it was
speculative investments, but these (tech) companies actually return
money to shareholders," she said.
"Tech deserves the leadership; the stock market is rewarding
growth."
BIOTECH THE FLIP SIDE TO TECH STOCK LEADERSHIP
While technology stocks have led the market recovery, biotech stocks
have been a drag on performance.
The Nasdaq Biotech Index is down 3.5 percent from its Aug. 25 close,
and more than 20 percent below its year high. The three index
components with the largest declines in market capitalization in the
last eight weeks are Mylan, Illumina and Biogen.
"There has been a major rotation out of healthcare and into tech and
it has continued after the recent earnings reports," said Wedbush's
James, referring to strong results from Amazon, Microsoft and
Alphabet.
Biotech stocks were shaken in September when U.S. presidential
candidate Hillary Clinton first tweeted concerns about drug prices
and the selling spread to other areas of the healthcare sector.
Investors have been dumping shares of everything from hospitals to
traditional pharmaceutical companies and insurers in recent weeks.
Since peaking in July, the Nasdaq Biotech Index has fallen 23
percent, the broad S&P Health Care Index has lost 12 percent and the
S&P 500 Health Care Facilities index is down 31 percent.
Fund managers now say they expect regulatory threats on drug prices,
disappointing earnings, higher interest rates that could hurt
heavily indebted hospitals, and the loss of the initial Obamacare
boost to business to all weigh on health sector stocks this year.
(Reporting by Rodrigo Campos; Editing by Clive McKeef)
[© 2015 Thomson Reuters. All rights
reserved.] Copyright 2015 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed. |
